Anetumab ravtansine

Drug Profile

Anetumab ravtansine

Alternative Names: Anti-mesothelin antibody-drug conjugate BAY 94-9343; Anti-mesothelin-ADC-BAY-94-9343; BAY-94-9343; BAY-94-9343-SPDB-DM4

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; ImmunoGen; MorphoSys; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Mesothelioma; Pancreatic cancer; Solid tumours
  • Phase I Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 04 Jul 2017 Bayer completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan (IV) (NCT02485119)
  • 26 May 2017 Phase-I clinical trials in Solid tumours (Recurrent, Late-stage disease, Combination therapy) in South Korea (IV) (NCT03102320)
  • 26 May 2017 Phase-I clinical trials in Solid tumours (Recurrent, Late-stage disease, Monotherapy) in South Korea (IV) (NCT03102320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top